世界の化学療法誘発性末梢神経障害治療販売市場2021

QYResearchが発行した調査報告書(QYR21JN7615)
◆英語タイトル:Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Report 2021
◆商品コード:QYR21JN7615
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年3月23日(※2024年版があります。お問い合わせください。)
◆ページ数:144
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD6,000 ⇒換算¥888,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD8,000 ⇒換算¥1,184,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

QYリサーチ社の本調査レポートでは、世界の化学療法誘発性末梢神経障害治療市場について種類別(カルシウムチャネルα2-デルタリガンド、抗うつ薬、オピオイド、その他)、用途別(プラチナ剤、タキサン、ビンカアルカロイド、その他)、地域別(アメリカ、ヨーロッパ、中国、日本、東南アジア、インド)に区分して調査し、纏めました。2016年~2027年までの市場規模と予測(販売量、売上、価格)、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。
・化学療法誘発性末梢神経障害治療市場の概要
・世界の主要地域別化学療法誘発性末梢神経障害治療市場規模2016-2027
・主要プレイヤーの競争状況・市場シェア
・世界の化学療法誘発性末梢神経障害治療市場規模2016-2021:種類別(カルシウムチャネルα2-デルタリガンド、抗うつ薬、オピオイド、その他)
・世界の化学療法誘発性末梢神経障害治療市場予測2012-2027:種類別(カルシウムチャネルα2-デルタリガンド、抗うつ薬、オピオイド、その他)
・世界の化学療法誘発性末梢神経障害治療市場規模2016-2021:用途別(プラチナ剤、タキサン、ビンカアルカロイド、その他)
・世界の化学療法誘発性末梢神経障害治療市場予測2012-2027:用途別(プラチナ剤、タキサン、ビンカアルカロイド、その他)
・化学療法誘発性末梢神経障害治療のアメリカ市場規模と予測2016-2021
・化学療法誘発性末梢神経障害治療のヨーロッパ市場規模と予測2016-2021
・化学療法誘発性末梢神経障害治療の中国市場規模と予測2016-2021
・化学療法誘発性末梢神経障害治療の日本市場規模と予測2016-2021
・化学療法誘発性末梢神経障害治療の東南アジア市場規模と予測2016-2021
・化学療法誘発性末梢神経障害治療のインド市場規模と予測2016-2021
・主要プレイヤーの企業情報:事業概要・売上・企業動向
(Aptinyx Inc、Asahi Kasei Pharma Corp、Regenacy Pharmaceuticals、MAKScientific LLC、Metys Pharmaceuticals AG、Nemus Bioscience Inc、PledPharma、Sova Pharmaceuticals Inc、DermaXon LLC、Kineta Inc、Krenitsky Pharmaceuticals Inc、PeriphaGen、Apexian Pharma、WinSanTor、Solasia Pharma K.K.)
・化学療法誘発性末梢神経障害治療の製造コスト分析
・販売チャネル、流通業者、顧客
・化学療法誘発性末梢神経障害治療の市場動向・機会・課題
・調査の結論
【レポートの概要】

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
By region, the United States has the highest share of income, reaching 47.25 percent in 2019.

Market Analysis and Insights: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market
The global Chemotherapy Induced Peripheral Neuropathy Treatment market was valued at US$ 1669.5 in 2020 and will reach US$ 2422.3 million by the end of 2027, growing at a CAGR of 6.4% during 2022-2027.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Scope and Market Size
The global Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Induced Peripheral Neuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others

Segment by Application
Platinum Agents
Taxanes
Vinca Alkaloids
Others

The Chemotherapy Induced Peripheral Neuropathy Treatment market is analysed and market size information is provided by regions (countries). Segment by Application, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Solasia Pharma K.K.

【レポートの目次】

1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product Scope
1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2016 & 2021 & 2027)
1.2.2 Calcium Channel α2-delta Ligands
1.2.3 Antidepressants
1.2.4 Opioids
1.2.5 Others
1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Platinum Agents
1.3.3 Taxanes
1.3.4 Vinca Alkaloids
1.3.5 Others
1.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts (2016-2027)
1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Trends (2016-2027)

2 Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Forecasts by Region
2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2016-2021)
2.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2016-2021)
2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
2.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
2.4.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
2.4.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
2.4.6 India Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2016-2027)
3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Competition Landscape by Players
3.1 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Sales (2016-2021)
3.2 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Revenue (2016-2021)
3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2020)
3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Company (2016-2021)
3.5 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Review by Type (2016-2021)
4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2021)
4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2016-2021)
4.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2016-2021)
4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Type (2022-2027)
4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Type (2022-2027)
4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Type (2022-2027)
5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Review by Application (2016-2021)
5.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2021)
5.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2016-2021)
5.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2016-2021)
5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2022-2027)
5.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Application (2022-2027)
5.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Application (2022-2027)

6 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
6.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
6.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
6.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
6.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
6.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
6.2.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
6.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
6.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2016-2021)
6.3.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2022-2027)

7 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
7.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
7.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
7.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
7.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
7.3.1 Europe 144 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 144 Sales Breakdown by Application (2022-2027)

8 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
8.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
8.1.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
8.1.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
8.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
8.2.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
8.2.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
8.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
8.3.1 China 313 Sales Breakdown by Application (2016-2021)
8.3.2 China 313 Sales Breakdown by Application (2022-2027)

9 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
9.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
9.1.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
9.1.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
9.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
9.2.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
9.2.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
9.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
10.1 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
10.1.1 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
10.1.2 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
10.2 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
10.2.1 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)

11 India Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
11.1 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company
11.1.1 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2016-2021)
11.1.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2016-2021)
11.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type
11.2.1 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2016-2021)
11.2.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Type (2022-2027)
11.3 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application
11.3.1 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2016-2021)
11.3.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Chemotherapy Induced Peripheral Neuropathy Treatment Business
12.1 Aptinyx Inc
12.1.1 Aptinyx Inc Corporation Information
12.1.2 Aptinyx Inc Business Overview
12.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.1.5 Aptinyx Inc Recent Development
12.2 Asahi Kasei Pharma Corp
12.2.1 Asahi Kasei Pharma Corp Corporation Information
12.2.2 Asahi Kasei Pharma Corp Business Overview
12.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.2.5 Asahi Kasei Pharma Corp Recent Development
12.3 Regenacy Pharmaceuticals
12.3.1 Regenacy Pharmaceuticals Corporation Information
12.3.2 Regenacy Pharmaceuticals Business Overview
12.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.3.5 Regenacy Pharmaceuticals Recent Development
12.4 MAKScientific LLC
12.4.1 MAKScientific LLC Corporation Information
12.4.2 MAKScientific LLC Business Overview
12.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.4.5 MAKScientific LLC Recent Development
12.5 Metys Pharmaceuticals AG
12.5.1 Metys Pharmaceuticals AG Corporation Information
12.5.2 Metys Pharmaceuticals AG Business Overview
12.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.5.5 Metys Pharmaceuticals AG Recent Development
12.6 Nemus Bioscience Inc
12.6.1 Nemus Bioscience Inc Corporation Information
12.6.2 Nemus Bioscience Inc Business Overview
12.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.6.5 Nemus Bioscience Inc Recent Development
12.7 PledPharma
12.7.1 PledPharma Corporation Information
12.7.2 PledPharma Business Overview
12.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.7.5 PledPharma Recent Development
12.8 Sova Pharmaceuticals Inc
12.8.1 Sova Pharmaceuticals Inc Corporation Information
12.8.2 Sova Pharmaceuticals Inc Business Overview
12.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.8.5 Sova Pharmaceuticals Inc Recent Development
12.9 DermaXon LLC
12.9.1 DermaXon LLC Corporation Information
12.9.2 DermaXon LLC Business Overview
12.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.9.5 DermaXon LLC Recent Development
12.10 Kineta Inc
12.10.1 Kineta Inc Corporation Information
12.10.2 Kineta Inc Business Overview
12.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.10.5 Kineta Inc Recent Development
12.11 Krenitsky Pharmaceuticals Inc
12.11.1 Krenitsky Pharmaceuticals Inc Corporation Information
12.11.2 Krenitsky Pharmaceuticals Inc Business Overview
12.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.11.5 Krenitsky Pharmaceuticals Inc Recent Development
12.12 PeriphaGen
12.12.1 PeriphaGen Corporation Information
12.12.2 PeriphaGen Business Overview
12.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.12.5 PeriphaGen Recent Development
12.13 Apexian Pharma
12.13.1 Apexian Pharma Corporation Information
12.13.2 Apexian Pharma Business Overview
12.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.13.5 Apexian Pharma Recent Development
12.14 WinSanTor
12.14.1 WinSanTor Corporation Information
12.14.2 WinSanTor Business Overview
12.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.14.5 WinSanTor Recent Development
12.15 Solasia Pharma K.K.
12.15.1 Solasia Pharma K.K. Corporation Information
12.15.2 Solasia Pharma K.K. Business Overview
12.15.3 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.15.5 Solasia Pharma K.K. Recent Development

13 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Cost Analysis
13.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
13.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
14.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers

15 Market Dynamics
15.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
15.2 Chemotherapy Induced Peripheral Neuropathy Treatment Drivers
15.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
15.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の化学療法誘発性末梢神経障害治療販売市場2021(Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Report 2021)]についてメールでお問い合わせはこちらでお願いします。